Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.
about
Antigen-Sparing and Enhanced Efficacy of Multivalent Vaccines Adjuvanted with Immunopotentiators in Chickens.Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection.Respiratory syncytial virus genotypes circulating in urban Ghana: February to November 2006.Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractAn overview of adjuvant formulations and delivery systems.Intranasal formulations: promising strategy to deliver vaccines.Novel therapies and vaccines against the human respiratory syncytial virus.Recent advances in the development of subunit-based RSV vaccines.Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination.An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.Signaling via pattern recognition receptors NOD2 and TLR2 contributes to immunomodulatory control of lethal pneumovirus infectionLipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection.Nod2 is required for antigen-specific humoral responses against antigens orally delivered using a recombinant Lactobacillus vaccine platform.
P2860
Q33729299-2F4EC254-3906-45A9-B16D-A52B4C17591FQ34306309-7AA97470-0284-455B-AFDD-2770252A5BB8Q35123752-6774589D-D83C-4161-A2A2-FE9AF1B88757Q35690781-8E257B52-55A1-4E22-9FBE-468ABE7DA9B2Q38126953-6FDDA5D8-1626-49E6-AF58-FCAD56940303Q38223050-FCB75BCD-2A59-4F13-ACEE-2857D81B7A99Q38604787-A6E4ABA3-422C-4325-89DF-EF64A059DE4EQ38617302-2D709DE1-1F53-4554-981E-278A0C61B70CQ38803541-73C87DD5-0A8E-4F91-8A15-136CA96E0584Q38818697-E1EE2C74-7DDE-4802-95CD-55F3B43E5AE1Q38971243-E4FF5FB6-6CE4-4844-98E9-F4B46E7011C7Q40696627-55EED2F2-C388-40EE-997D-2FDD99674079Q52725104-2F968D4C-1FD0-4A03-8DFD-058E830549CDQ55116645-35823968-1CF7-4B8C-82F9-652EA3F22C0F
P2860
Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Evaluation of an intranasal vi ...... and mucosal immune responses.
@ast
Evaluation of an intranasal vi ...... and mucosal immune responses.
@en
Evaluation of an intranasal vi ...... and mucosal immune responses.
@nl
type
label
Evaluation of an intranasal vi ...... and mucosal immune responses.
@ast
Evaluation of an intranasal vi ...... and mucosal immune responses.
@en
Evaluation of an intranasal vi ...... and mucosal immune responses.
@nl
prefLabel
Evaluation of an intranasal vi ...... and mucosal immune responses.
@ast
Evaluation of an intranasal vi ...... and mucosal immune responses.
@en
Evaluation of an intranasal vi ...... and mucosal immune responses.
@nl
P2860
P1433
P1476
Evaluation of an intranasal vi ...... and mucosal immune responses.
@en
P2093
Aalzen de Haan
Muhammad Shafique
P2860
P304
P356
10.1371/JOURNAL.PONE.0061287
P407
P577
2013-04-08T00:00:00Z